Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% ...

Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...

With a market cap of $122.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) operates as a global biotechnology company ...

Global Data has revealed that the Top 20 Global Biopharmaceutical Companies have witnessed a 6 % growth in market ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff ...

Casgevy and Journavx are poised to become significant growth drivers for Vertex Pharmaceuticals in the coming years, marking pivotal steps in the company's push to diversify its portfolio.

Vertex Pharmaceuticals Incorporated ... of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic ...

The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex Pharmaceuticals' (NASDAQ:VRTX) non-opioid pain medicine Journavx (suzetrigine).

It also seems to have a knack for filling those needs, as the apparent robust demand for Journavx indicates ... for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them.